3rd Annual Pharma/Life Science Virtual Summit

In the healthcare industry, cannabis holds promising therapeutic benefits for various health conditions; however, regulatory implications and evidence-based regulations must be carefully considered and developed to ensure safe and responsible use. In this keynote presentation, Peter Grinspoon, MD, primary care physician, educator, and cannabis specialist at Massachusetts General Hospital; an instructor at Harvard Medical School; and a certified health and wellness coach, reveals the truth about cannabis and sheds light on its potential benefits and risks. He will also discuss the therapeutic potential of cannabis, responsible usage, and the impact of cannabis legalization on the healthcare system and patient care.

Learning Objectives
• Discover the therapeutic potential of cannabis for chronic health conditions and gain an understanding of the importance of responsible use
• Explore the risks and challenges associated with cannabis use, with a particular focus on addiction and recovery
• Engage in a discussion about the impact of cannabis legalization on healthcare and patient care, emphasizing the need for evidence-based regulations and further research in the field

Join this webinar to learn about the current trends shaping the specialty pharmacy market, and how these pharmacies will change in the coming 5-10 years. This session will focus on the shifting landscape of specialty medications, the evolving demands on specialty pharmacies, and opportunities for collaboration between stakeholders such as specialty pharmacies, pharmaceutical manufacturers, health plans, and PBMs.

Things you’ll learn:
• How stakeholders will need to partner and collaborate to meet new challenges
• Where the specialty pharmacy market currently stands, and our predictions on where it’s headed
• Which disruptors are worth watching in the specialty pharmacy market

The accessibility and affordability of biologics and biosimilars are greatly influenced by the dynamics and pricing differences within the prescription drug supply chain. These factors can impede the adoption of biosimilars, leading to reduced competition and fewer cost savings for patients and healthcare systems. Ross Day, RPH, DP, former Director of Pharmacy at Vizient and current pharmaceutical consultant, and Antonio Ciaccia, CEO and co-founder of 46brooklyn, President of 3 Axis Advisors, will explore the dynamics of the prescription drug supply chain and pricing disparities related explicitly to biologics and biosimilars during this panel discussion.

Learning Objectives
• Gain comprehensive insight into the profound impact of prescription drug chain dynamics and pricing disparities on the accessibility and affordability of biologics and biosimilars
• Explore the intricacies surrounding barriers to biosimilar adoption and their far-reaching effects on market competition
• Engage in meaningful discussions to devise effective strategies for mitigating pricing disparities, enhancing access to biologics and biosimilars, and realizing substantial cost savings for patients and healthcare systems